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THE OUTBREAK OF WEST NILE VIRUS INFECTION
























































































































































In late August 1999, an unusual clus-
ter of cases of meningoencephalitis associated with
muscle weakness was reported to the New York City
Department of Health. The initial epidemiologic and





Active surveillance was implemented to
identify patients hospitalized with viral encephalitis
and meningitis. Cerebrospinal fluid, serum, and tis-
sue specimens from patients with suspected cases





Outbreak surveillance identified 59 pa-
tients who were hospitalized with West Nile virus in-
fection in the New York City area during August and
September of 1999. The median age of these patients
was 71 years (range, 5 to 90). The overall attack rate
of clinical West Nile virus infection was at least 6.5
cases per million population, and it increased sharply
with age. Most of the patients (63 percent) had clin-
ical signs of encephalitis; seven patients died (12 per-
cent). Muscle weakness was documented in 27 per-
cent of the patients and flaccid paralysis in 10 percent;
in all of the latter, nerve conduction studies indicated
an axonal polyneuropathy. An age of 75 years or old-
er was an independent risk factor for death (relative
risk adjusted for the presence or absence of diabetes
mellitus, 8.5; 95 percent confidence interval, 1.2 to
59.1), as was the presence of diabetes mellitus (age-
adjusted relative risk, 5.1; 95 percent confidence in-




This outbreak of West Nile meningo-
encephalitis in the New York City metropolitan area
represents the first time this virus has been detected
in the Western Hemisphere. Given the subsequent
rapid spread of the virus, physicians along the eastern
seaboard of the United States should consider West
Nile virus infection in the differential diagnosis of en-
cephalitis and viral meningitis during the summer
months, especially in older patients and in those with
muscle weakness. (N Engl J Med 2001;344:1807-14.)
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N late August 1999, a specialist in infectious
diseases contacted the New York City Depart-
ment of Health about two patients with enceph-
alitis at a hospital in northern Queens. A pre-
liminary epidemiologic investigation at the nearby
hospitals identified six additional cases of encephali-
tis. These eight cases occurred among previously





ed with a febrile illness followed by changes in men-
tal status. All but one had severe muscle weakness.
Four had flaccid paralysis requiring ventilatory sup-





 Hematologic and biochemical
tests of patients’ cerebrospinal fluid suggested viral
infection as the cause.









) area in northern Queens. Inter-
views with the patients’ families revealed no obvious
common exposures. However, all patients had report-
edly engaged in outdoor activities (e.g., gardening)
around their homes in the evenings. An environmen-
tal investigation revealed the presence of culex mos-
quito breeding sites and larvae in many of the pa-
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findings, an arthropod-borne virus (arbovirus) was
suspected as the cause of this cluster of cases of en-
cephalitis.
When specimens were tested for arboviruses that
are common in eastern North America, specimens
from all eight patients had positive results on enzyme-
linked immunosorbent assay (ELISA) for IgM anti-
body against St. Louis encephalitis virus, a common
flavivirus that is enzootic in North America. The lab-
oratory, clinical, and epidemiologic data indicated that
the outbreak in New York City was most consistent
with an outbreak of St. Louis encephalitis, and mos-




Before and during the investigation of the enceph-
alitis cluster, an epizootic disease associated with the
death of substantial numbers of birds was occurring
in the New York City area. These deaths were initially
assumed to be unrelated to the outbreak in humans,
because St. Louis encephalitis virus does not nor-
mally kill its avian reservoir hosts. An independent
investigation of dead birds by veterinarians and wildlife
specialists in September found pathological evidence
of multiorgan involvement, including encephalitis, but
specimens obtained at necropsy tested negative for
common avian pathogens. Four weeks after the rec-
ognition of the outbreak in humans, a flavivirus, later
identified as West Nile virus, was isolated from tissue
specimens obtained from American crows in West-





 and was subsequently determined to be the com-





West Nile virus belongs to the Japanese encepha-
litis serogroup of flaviviruses that includes the St.
Louis encephalitis, Kunjin, and Murray Valley en-
cephalitis viruses, each of which is antigenically close-




 This report summariz-
es the findings of an epidemiologic investigation of
the 1999 outbreak of West Nile virus disease in the
New York City metropolitan area, which was the first







Hospitals in New York City and neighboring counties were
asked to report any suspected cases of viral infections of the cen-
tral nervous system. Counties were asked, through weekly broad-
cast-facsimile alerts, to report all suspected cases. Patients with sus-
pected cases were defined as those who were hospitalized on or
after August 1, 1999, with a presumptive diagnosis of viral enceph-
alitis (indicated by fever, altered mental status or other cortical
signs, and abnormal findings on analysis of cerebrospinal fluid),
aseptic meningitis (fever, meningeal signs, and abnormal findings
on analysis of cerebrospinal fluid), or Guillain–Barré syndrome
associated with fever. The abnormal findings in cerebrospinal fluid
that were considered to be indicative of a viral infection were a
protein concentration of at least 40 mg per deciliter or a white-
cell count of at least 5 per cubic millimeter, a negative Gram’s
stain, and a negative bacterial culture.
In addition, active surveillance to identify patients who met the
clinical criteria included weekly telephone inquiries to adult and
pediatric clinical staff in up to nine specialty areas (e.g., infectious
disease and neurology) at each hospital. Specimens of cerebrospinal
fluid and serum were requested from patients who met the clini-
cal criteria. A serum specimen obtained during the convalescent
phase was requested if an initial specimen, which had been ob-
tained within eight days after the onset of illness from any patient
who met the clinical criteria, tested negative for antibodies against
West Nile virus. For patients who had been discharged, serum sam-




Samples of serum and cerebrospinal fluid were tested with an
IgM-capture ELISA and an indirect IgG ELISA for antibodies





dition, specimens of cerebrospinal fluid and tissue were tested by
standard reverse-transcriptase polymerase chain reaction (RT-PCR)





; we also attempted to isolate virus from clinical spec-






The finding of any of the following was considered to represent





isolation by culture of West Nile virus or the amplification by RT-
PCR of West Nile virus RNA from human-tissue specimens; the
demonstration of IgM antibodies against West Nile virus in cer-
ebrospinal fluid by IgM-capture ELISA; an increase by more than
a factor of four in the titer of neutralizing antibody specific for
West Nile virus, as measured by the plaque-reduction neutraliza-
tion assay in paired serum or cerebrospinal fluid samples obtained
at appropriate times; or the detection in a single serum specimen of
both IgM and IgG antibodies against West Nile virus on ELISA
(and, for IgG, confirmed by a plaque-reduction neutralization as-
say). Patients with a single serum sample in which only IgM an-
tibodies to West Nile virus were detected were classified as having
a probable recent infection. Patients with a single serum specimen
in which only IgG antibodies to West Nile virus were detected
were also classified as having a probable recent West Nile virus in-
fection acquired in the New York area if the antibodies were con-
firmed by plaque-reduction neutralization assay to be specific to
West Nile virus and if the patient had no history of recent travel to
an area where the virus was endemic.
Patients were classified as having hypertension, diabetes melli-
tus, coronary artery disease, alcoholism, or immunosuppression if
a history of these conditions was noted in their medical record.
Patients were also classified as having a history of immunosup-
pression if any of the following conditions were present: cancer, hu-
man immunodeficiency virus (HIV) infection, treatment with cor-
ticosteroids, or alcoholism. Patients with encephalitis were classified
as having muscle weakness if neurologic examinations revealed
flaccid paralysis, decreased strength, or hyporeflexia.
 
Collection and Analysis of Epidemiologic and Clinical Data
 
Interviews were conducted with the patients or their proxies to
ascertain the epidemiologic and demographic risk factors for ar-
boviral infection. The medical records of all hospitalized patients
with laboratory evidence of West Nile virus infection were reviewed
with the use of a standardized form for abstracting information from
medical charts. If a sign or symptom was not specifically noted in
the medical record, it was considered to be absent.
The attack rates of West Nile virus disease per million population,
stratified according to age and borough or county, were calculat-




 The crude relative risks
and the relative risks adjusted according to the Mantel–Haenszel
method were calculated to examine the associations of age, histo-
ry of immunosuppression, and the presence or absence of coro-
nary artery disease, diabetes, or hypertension with the severity of
disease and mortality. Statistical analyses were performed with the
use of SAS software for Windows and Macintosh.
 
16,17
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Reports on 719 patients with clinical syndromes
of meningitis and encephalitis were received by the
health departments in New York City (589 patients),
Nassau County (70 patients), and Westchester Coun-
ty (60 patients), including 71 patients younger than
18 years old. In 62 of these 719 patients (9 percent),
there was laboratory evidence of recent West Nile vi-
rus infection. Three of these patients had a mild ill-
ness, with symptoms that consisted of only fever and
headache, which did not result in hospitalization. This
report focuses on the 59 hospitalized patients with
West Nile virus infection.
Cerebrospinal fluid specimens were available from
32 of the 59 patients: 30 of these (94 percent) were
positive for IgM antibodies against West Nile virus.
Serum specimens were also obtained from 29 of the
30 patients with IgM-positive cerebrospinal fluid spec-
imens; all of these serum specimens were IgM-posi-
tive. The two patients with IgM-negative cerebrospinal
fluid specimens had IgM-positive serum specimens.
Of the 19 cerebrospinal fluid specimens that were
obtained from patients within eight days after the on-
set of illness, 17 (89 percent) were positive for IgM
antibodies against West Nile virus. 
For 27 of the patients, no cerebrospinal fluid spec-
imen was available; viral infection in these patients
was confirmed on the basis of the finding of IgM an-
tibodies in the serum. The serologic diagnosis in pa-
tients from whom no cerebrospinal fluid specimens
had been obtained was confirmed by plaque-reduc-
tion neutralization assay. No cases were positive by
isolation of virus from brain tissue or cerebrospinal
fluid specimens. Among the specimens with sufficient
quantity to allow for real-time RT-PCR testing, 16
of 28 cerebrospinal fluid specimens (57 percent) and
4 of 28 serum specimens (14 percent) were positive
for West Nile virus genome. In all the patients who
died in whom autopsies were performed, the brain
tissue was positive for West Nile virus antigen on im-
munohistochemical analysis, and positive for West Nile




The median age of the hospitalized patients was
71 years (range, 5 to 90), and most of them (88 per-
cent) were at least 50 years old (Table 1). The overall
attack rate of clinical West Nile virus infection was at
least 6.5 cases per million population. The most cas-
es (32) and the highest rate of hospitalization (16.4
per million population) occurred in the New York
City borough of Queens. The onset of illness ranged
from August 2 through September 24, 1999 (Fig. 1),
with the peak of the outbreak occurring in mid-to-
late August. The attack rate of clinical infection in-
creased sharply with age, and the attack rate in per-
sons 50 years old or older was almost 20 times as
high as that in persons younger than 50 years old (rate
ratio, 19.6; 95 percent confidence interval, 17.9 to
21.6). Of the 59 hospitalized patients, 44 resided in
New York City, 14 lived in two adjacent counties of
New York state, and 1 was a tourist from Canada who
arrived in New York City on September 1, departed
on September 5 after visiting Queens, and became
ill on the airplane (which suggests an incubation pe-
riod of less than five days).
Interviews were completed with 56 of the 59 pa-
tients (95 percent). Only three (5 percent) reported
having traveled outside the United States (to Aruba,
St. Martin, and Canada) during the month before the
onset of illness. Only 18 patients (32 percent) re-
called being bitten by mosquitoes during the month




Of the 59 patients, 37 (63 percent) had encepha-
litis, 17 (29 percent) had meningitis without enceph-
alitis, and 5 (8 percent) had illness characterized by
fever and headache (Table 2). The mean duration of
symptoms before hospitalization was 5.3 days. Near-
ly all the patients presented with fever (90 percent;
temperature range, 36.5°C to 40.2°C); other symp-
toms included weakness (56 percent), nausea (53 per-
cent), vomiting (51 percent), headache (47 percent),
altered mental status (46 percent), and stiff neck (19
percent). A rash was reported in 11 patients (19 per-
cent) and was described as an erythematous macular,
papular, or morbilliform eruption involving some
combination of the neck, the trunk, and the arms
and legs.
Underlying chronic medical conditions included hy-
pertension (in 42 percent of the patients), diabetes
mellitus (in 20 percent), coronary artery disease (in 20
percent), and a history of known immunosuppression
(in 14 percent) (Table 2). The immunosuppression was





one patient), the use of prednisone for asthma (in one
patient), and alcoholism (in one patient).
Complete blood counts on admission showed no
substantial abnormalities (Table 3). However, the
cerebrospinal fluid findings were typical of a viral in-
fection: pleocytosis (mean cerebrospinal fluid white-
cell count, 38.2 per cubic millimeter; range, 0 to 525)
and an elevated protein concentration (mean, 104.2
mg per deciliter; range, 38 to 899).
Computed tomographic scans of the brain were
obtained for 43 patients (73 percent); they showed
no evidence of acute disease (Table 4). Magnetic res-
onance imaging of the brain was performed in 16
patients (27 percent); in 5 of these patients (31 per-
cent), the scans showed an enhancement of the lep-
tomeninges, the periventricular areas, or both.
Muscle involvement was documented by neurolog-
ic examination as decreased muscle strength (in 27
The New England Journal of Medicine 
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percent of patients) and hyporeflexia (in 32 percent)
and was more common among the patients with en-
cephalitis. Diffuse, flaccid paralysis occurred in 10
percent of the patients, with no discernible ascend-
ing or descending pattern of progression. Abnormal
findings consistent with an axonal polyneuropathy
were noted in 8 of the 10 patients who underwent
electrophysiologic testing, with decreased nerve con-
duction velocity of motor or sensory nerves or both
and diminished compound muscle action potentials
and fibrillation potentials on electromyography.
Among the 589 patients with suspected West Nile
virus infection reported in New York City, those with
encephalitis accompanied by muscle weakness were
more likely to be seropositive for West Nile virus (27
percent) than were patients with encephalitis alone
(14 percent) or aseptic meningitis (6 percent) (P for
trend <0.001).
 
Factors Predictive of Disease Severity and Prognosis
 
The analyses of potential risk factors for severe
disease (defined as encephalitis with muscle weakness)
and death are shown in Table 5. Only an age of 75
years or older was associated with a significantly high-
er likelihood of having encephalitis with muscle weak-
ness (relative risk, 2.7; 95 percent confidence interval,
1.3 to 5.8). Of the 59 patients, 7 died, for an overall
case fatality rate of 12 percent. Among the patients
with encephalitis who also had muscle weakness, the
case fatality rate was 30 percent, with six of the sev-
en deaths occurring in patients with encephalitis and
muscle weakness. An age of 75 years or older was the
factor most strongly associated with death (relative
risk adjusted for the presence or absence of diabetes
mellitus, 8.5; 95 percent confidence interval, 1.2 to
59.1). The presence of diabetes mellitus was also sig-
nificantly associated with death, even after adjustment
for age (age-adjusted relative risk, 5.1; 95 percent




Autopsy reports on the four patients from New
York City who died, as well as immunohistochemical
analysis of cortical tissue, showed only minimal evi-
 
*Population figures are from the 1990 U.S. Census. 
†CI denotes confidence interval. 
‡This group served as the reference population.























































































































































0–19‡ 2 (3) 2,324,081 0.9 1.0 
20–29 1 (2) 1,553,981 0.6 0.8 (0.2–3.7)
30–39 3 (5) 1,549,111 1.9 2.3 (1.1–4.6)
40–49 1 (2) 1,177,190 0.8 1.0 (0.2–4.9)
50–59 9 (15) 867,331 10.4 12.1 (9.1–15.9)
60–69 13 (22) 814,838 16.0 18.5 (15.2–22.6)
70–79 18 (31) 534,785 33.7 39.1 (33.8–45.3)
»80 12 (20) 281,054 42.7 49.6 (40.1–61.5)
Age category (yr)
»50 52 (88) 2,498,008 20.8 19.6 (17.9–21.6)
<50‡ 7 (12) 6,604,363 1.1 1.0 
Sex
Male 31 (53) 4,289,988 7.2 1.2 (1.0–1.6)
Female‡ 28 (47) 4,812,383 5.8 1.0 
Race
White 41 (69) 5,983,901 6.9 2.4 (1.3–4.4)
Nonwhite‡ 9 (15) 3,118,470 2.9 1.0 
Unknown 9 (15) — —
Borough or county of residence
New York City
Brooklyn (Kings)‡ 3 (5) 2,300,664 1.3 1.0 
Bronx 9 (15) 1,203,789 7.5 5.7 (4.1–8.0)
Manhattan 1 (2) 1,487,536 0.7 0.5 (0.1–2.8)
Queens 32 (54)§ 1,951,599 16.4 12.6 (11.4–13.9)
Staten Island (Richmond) 0 379,999 0.0 —
New York State
Nassau 6 (10) 1,287,348 4.7 3.6 (2.3–5.7)
Westchester 8 (14) 874,866 9.1 7.0 (4.9–10.1)
The New England Journal of Medicine 
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dence of West Nile virus infection was more likely to
be found in the brain stem than in other sites in the
brain or in extraneural tissue. In the most severe case,
there was evidence of scattered microglial nodules;
perivascular and perineuronal inflammation, primar-
ily confined to the medulla and the cranial-nerve
roots, was also present.19 One patient was found on
postmortem examination to have hemorrhagic pan-
creatitis. Autopsy did not reveal evidence of hepatitis
or myocarditis.
TABLE 3. SELECTED LABORATORY RESULTS FOR 59 PATIENTS 
HOSPITALIZED WITH WEST NILE VIRUS INFECTION 
IN THE NEW YORK CITY AREA IN 1999.




White-cell count (¬10¡3/mm3) 10.4±4.9 2.3–30.8 3.2–9.8
Hemoglobin (g/dl) 13.5±1.7 9.0–16.7 11.5–18.0
Hematocrit (%) 39.1±6.0 10.2–50.2 33.0–49.0
Lymphocytes (%) 14.1±7.3 3.0–38.0 >25.0
Cerebrospinal fluid
Interval between onset and
collection (days)
9.3±7.2 0–24 —
Protein (mg/dl) 104.2±117.2 38.0–899.0 15.0–50.0
White-cell count (per mm3) 38.2±11.6 0–525 0–10
Lymphocytes (%) 47.4±29.0 4.0–92.0 63.0–99.0
Glucose (mg/dl) 79.8±20.9 46.0–143.0 40.0–80.0
Figure 1. Numbers of Patients Hospitalized with West Nile Virus
Infection (Epidemic Curve) in the New York City Metropolitan
Area in 1999.
Hatched boxes represent patients who resided in New York
City, and light gray boxes represent patients who resided in








































































TABLE 2. CLINICAL CHARACTERISTICS OF 59 PATIENTS 
HOSPITALIZED WITH WEST NILE VIRUS INFECTION 






With weakness 20 (34)
Without weakness 17 (29)
Aseptic meningitis without encephalitis 17 (29)
Fever and headache 5 (8)
Signs and symptoms














Slurred speech 5 (8)
Abdominal pain 4 (7)








Coronary artery disease 12 (20)
Known immunosuppression 8 (14)
Dementia 3 (5)
Head trauma 2 (3)
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DISCUSSION
West Nile virus is enzootic in Africa, Europe, and
Asia. Its typical reservoirs include a wide variety of
wild and domestic birds, and the vectors are mosqui-
toes of the culex species.20 Most West Nile virus in-
fections in humans are subclinical, with overt disease
estimated to occur in approximately 1 of every 100
infections.21 The incubation period ranges from 3 to
15 days.22 The resulting illness varies from mild ill-
ness (with fever, petechial rash, and headache) to
meningoencephalitis,9 and the likelihood that severe
neurologic illness will develop increases with age.23
Underlying medical conditions (e.g., hypertension)
may facilitate the passage of neurotropic flaviviruses
across the blood–brain barrier and may predispose
infected persons to neurologic complications.24-27 In
previous outbreaks, the case fatality rate among clin-
ical cases ranged from 4 percent to 13 percent and
was highest among elderly persons.20
This outbreak represents the first recognized oc-
currence of West Nile virus in the Western Hemi-
sphere. In areas where it is endemic, West Nile virus
usually causes outbreaks of milder febrile illness.9,28,29
The 1999 outbreak in the New York City area fol-
lowed a pattern more characteristic of recent out-
breaks of encephalitis in areas where the virus is not
endemic and where the level of immunity of the pop-
ulation to West Nile virus is lower (e.g., Romania
and Russia); in these outbreaks, recognized illness was
characterized by severe neurologic disease that af-
fected primarily older adults.20,30-34 Genetic analysis
indicated that the strain of West Nile virus responsi-
ble for this outbreak was similar to strains that have
caused outbreaks of encephalitis in northern Europe
and was nearly identical to a strain that was circulat-
ing in Israel in 1998.7 
In our study, older age was associated with a sub-
stantially higher risk of more severe neurologic dis-
ease, and both age and the presence of diabetes melli-
tus were significant risk factors for death. Decreasing
immunity is a consequence of aging as well as a com-
plication of diabetes mellitus, and both factors can
increase the host’s susceptibility to infections.35-38 The
relation we found between diabetes and the fatal out-
come of West Nile virus infections requires further
study.
The outbreak in the New York City area was un-
usual because profound muscle weakness was a com-
mon complication in the patients with encephalitis.
This unusual finding of profound muscle weakness
prompted the initial report of a cluster of cases of en-
cephalitis to the New York City Department of Health
and ultimately led to the recognition of a regional ep-
idemic and epizootic of West Nile virus infection.
Most of the mosquito pools that tested positive
for West Nile virus by RT-PCR and real-time RT-PCR
and from which virus could be isolated contained
both Culex pipiens and C. restuans mosquitoes39;
such pools were found in all the areas where cases
occurred among humans except Manhattan. How-
ever, West Nile virus infection in birds was much
more geographically widespread than indicated by
the distribution of the human cases and positive mos-
quito pools.40 Infected dead crows were found in ar-
eas where no human cases were detected, including
the lower Hudson Valley, eastern Long Island, Con-
necticut, New Jersey, and Baltimore. Serologic stud-
ies conducted in live wild birds in September 1999
demonstrated a direct geographic correlation between
the rates of West Nile meningoencephalitis in humans
and the prevalence of antibody against West Nile vi-
rus in birds that were tested in Queens (avian sero-
prevalence, 50 percent), Westchester County (11 per-
*CT denotes computed tomographic, and MRI magnetic resonance im-
aging. The denominators for CT scanning results, MRI results, and elec-
tromyelography and nerve conduction study results represent the numbers
of patients who underwent those tests. Hyporeflexia and hyperreflexia are
subcategories of abnormal deep-tendon reflexes.
TABLE 4. HOSPITAL COURSE IN 59 PATIENTS WITH WEST NILE 
VIRUS INFECTION IN THE NEW YORK CITY AREA IN 1999, 

















Normal 27/43 (63) 16/31 (52) 11/12 (92)
Atrophy or ischemic changes 16/43 (37) 15/31 (48) 1/12 (8)
Evidence of acute disease 0/43 0/31 0/12 
MRI results 
Normal 5/16 (31) 5/13 (38) 0/3  
Atrophy or ischemic changes 6/16 (38) 4/13 (31) 2/3  (67)
Meningeal enhancement 5/16 (31) 4/13 (31) 1/3  (33)
Abnormal cranial nerve function 13/59 (22) 11/37 (30) 2/22 (9)
Motor examination findings 
Abnormal strength 16/59 (27) 12/37 (32) 4/22 (18)
Flaccid paralysis 6/59 (10) 4/37 (11) 2/22 (9)
Abnormal deep tendon reflexes 23/59 (39) 16/37 (43) 7/22 (32)
Hyporeflexia 19/23 (83) 15/16 (94) 4/7  (57)
Hyperreflexia 4/23 (17) 1/16 (6) 3/7  (43)
Electromyelography and nerve 
conduction study results
Axonal neuropathy 8/10 (80) 5/6 (83) 3/4  (75)
Admitted to intensive care unit 19/59 (32) 16/37 (43) 3/22 (14)
Respiratory symptoms
Required oxygen 19/59 (32) 15/37 (41) 4/22 (18)
Required mechanical ventilation 10/59 (17) 9/37 (24) 1/22 (5)
Treatments
Plasmapheresis 3/59 (5) 2/37 (5) 1/22 (5)
Intravenous immune globulin 1/59 (2) 1/37 (3) 0/22 
Antibiotics 51/59 (86) 36/37 (97) 15/22 (68)
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cent), Nassau County (7 percent), Brooklyn (5 per-
cent), and Staten Island (2 percent).41
Recent data suggest that West Nile virus has be-
come enzootic in the northeastern United States. In
the winter after the 1999 outbreak, West Nile virus
was isolated from overwintering culex mosquitoes
collected in Queens.42,43 Surveillance of birds and
mosquitoes during 2000 showed extensive epizootic
activity centered in the New York City metropolitan
area and extending throughout much of the eastern
seaboard, with reports of dead birds that tested pos-
itive for West Nile virus from southern Vermont and
New Hampshire down to North Carolina. However,
a human outbreak of meningoencephalitis during the
late summer and early fall of 2000 was limited to New
York City (14 cases) and New Jersey (5 cases).43,44
West Nile virus will most likely spread beyond the
northeast and may cause sporadic cases or outbreaks
of West Nile virus disease in other regions of the
United States. During the mosquito season (from late
spring until the first sustained frost), physicians —
especially those along the eastern seaboard — should
consider West Nile virus disease in the differential
diagnosis of hospitalized patients with encephalitis
(especially when it is accompanied by muscle weak-
ness) and viral meningitis (especially in adults).43 Se-
rologic testing remains the most reliable diagnostic
method for West Nile virus infection in humans. Sus-
pected cases should be reported to local public health
departments, and appropriate laboratory specimens,
including cerebrospinal fluid and serum samples ob-
tained during the acute and convalescent phases, as
well as autopsy specimens, should be submitted to
state public health laboratories to be tested for West
Nile virus. Treatment is supportive.
The 1999 West Nile virus disease outbreak again
proves that, with the growing volume of international
travel and commerce, exotic pathogens can move be-
tween continents with increasing ease. Physicians, vet-
erinarians, laboratory workers, and public health of-
ficials must remain vigilant for unexpected outbreaks
of imported diseases in the future.
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APPENDIX
In addition to the authors, the members of the West Nile Outbreak Re-
sponse working group were as follows: N. Cohen, D. Cimini, A. Ramon,
I. Poshni, B. Maldin, A. Inglesby, A. Labowitz, K. Bornschlegel, E.
Samoff, M.C. Vargas, R. Bhalla, E. Lee, G. Sacajiu, D. Malebranche, A.
Sharma, M. Eisenberg, T. Chernesky, M. Volk, and D. Brown, New York
*Muscle weakness was defined by evidence of flaccid paralysis, abnormal strength, or hyporeflexia
on neurologic examination. The relative risks associated with a history of immunosuppression and
with the presence of coronary artery disease, hypertension, and diabetes mellitus have been adjusted
for age. PCR denotes polymerase chain reaction.
†Specimens of cerebrospinal fluid from 25 patients were available for testing by real-time reverse-
transcriptase PCR.
TABLE 5. RELATIVE RISKS OF MUSCLE WEAKNESS, ENCEPHALITIS WITH MUSCLE 
WEAKNESS, AND DEATH ASSOCIATED WITH VARIOUS PROGNOSTIC FACTORS 
IN 59 PATIENTS HOSPITALIZED WITH WEST NILE VIRUS INFECTION.*





Known history of immunosuppression 1.6 (1.0–2.6) 1.4 (0.4–11.1) 2.1 (0.5–8.1)
Coronary artery disease 1.2 (0.5–2.6) 1.4 (0.7–2.6) 2.0 (0.6–6.6)
Hypertension 1.6 (0.9–2.5) 1.2 (0.6–2.3) 2.1 (0.3–12.2)
Diabetes mellitus 1.0 (0.5–1.9) 1.3 (0.6–2.7) 5.1 (1.5–17.3)
Age »75 yr
Unadjusted 1.4 (0.8–2.3) 2.7 (1.3–5.8) 8.8 (1.1–68.1)
Adjusted for presence or absence 
of diabetes mellitus
1.4 (0.8–2.3) 2.4 (1.3–4.6) 8.5 (1.2–59.1)
Muscle weakness — — 4.6 (0.7–31.6)
Virus detected by PCR in cerebro-
spinal fluid†
0.7 (0.3–1.8) 2.3 (0.6–9.0) 1.0 (0.2–5.0)
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